Navigation Links
Certain Diabetes Drugs Better for Heart Health, Study Finds
Date:4/7/2011

By Serena Gordon
HealthDay Reporter

THURSDAY, April 7 (HealthDay News) -- The commonly used oral diabetes drug metformin not only helps stabilize blood sugar levels, it also may offer protection against heart disease, researchers say.

In a study that included more than 100,000 residents of Denmark taking metformin or another group of oral diabetes medications called insulin secretagogues (ISs), researchers found that metformin and the IS drugs gliclazide and repaglinide had the lowest risk of cardiovascular disease and death.

"Some medications, such as metformin, gliclazide and repaglinide, are more effective in reducing cardiovascular risk than the other medications," said Dr. Tina Ken Schramm, a senior resident at Copenhagen University Hospital in Denmark.

Dr. Darren McGuire, co-author of an editorial accompanying the study, agreed and said the study's findings are likely an indication that metformin, gliclazide and repaglinide are protective.

In previous research, metformin has been shown to reduce the risk of major adverse cardiac events and death by about 40 percent compared to placebo, he said. That means other drugs would have to offer a great deal of protection to compare favorably, he noted.

"If you compare a good drug against a great drug, the good drug doesn't necessarily look so good. But, if you compared the good drug to a placebo, the cardiovascular risk would probably be neutral," said McGuire, an associate professor in the division of cardiology at the University of Texas Southwestern Medical Center at Dallas.

Both experts said metformin is the recommended first line of treatment for someone with type 2 diabetes, and this study's findings support that recommendation.

Results of the study were published online April 6 in the European Heart Journal.

Although insulin secretagogues are widely prescribed for type 2 diabetes -- either alone or in combination with metformin -- information on their long-term cardiovascular effects is lacking, according to background information in the study.

To get a better idea of what impact, if any, these medications have on heart health, the researchers reviewed data on 107,806 people over 20 years old who lived in Denmark. All were taking an oral diabetes medication, such as metformin, glimepiride, gliclazide, glibenclamide (known as glyburide in the United States and Canada), glipizide, tolbutamide and repaglinide. Of this group, 9,607 people had experienced a previous cardiovascular event, such as a heart attack or stroke.

Compared to metformin, four of the drugs were more likely to be associated with an increased risk of all-cause mortality in people who hadn't had a previous cardiovascular event. The risk for glimepiride was 32 percent higher, while the risk was increased by 19 percent for glibenclamide. For glipizide the risk was 27 percent higher, and the risk of death was 28 percent higher for people taking tolbutamide versus metformin, according to the study. The risks were even higher in people taking these drugs who'd had a previous cardiovascular event.

The researchers also found that the risk of heart attack, stroke and cardiovascular death was higher in the people taking these medications.

The IS drugs gliclazide and repaglinide had risk profiles similar to metformin and didn't appear to be associated with an increased risk of death, heart attack or stroke.

"We demonstrated that for all outcomes, the ISs glimepiride, glibenclamide, glipizide and tolbutamide exhibited increased risk when compared to metformin, whereas there was no statistical difference in risk for gliclazide and repaglinide when compared to metformin," said Schramm.

McGuire cautioned that people shouldn't stop taking any type of diabetes medication on their own. If you're concerned, "have a discussion with your care provider," he said.

More information

Learn more about oral diabetes medications from the American Diabetes Association.

SOURCES: Tina Ken Schramm, M.D., senior resident, Copenhagen University Hospital, Denmark; Darren McGuire, M.D., associate professor, division of cardiology, department of internal medicine, University of Texas Southwestern Medical Center at Dallas; April 6, 2011, European Heart Journal, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Certain pain medications do not appear to be associated with skin cancer risk
3. AGA offers new recommendations for CRC surveillance for certain patients with IBD
4. Smoking significantly increases risk of aneurysm in people with certain genes
5. American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages
6. Certain Bone Drugs May Lower Breast Cancer Risk
7. Football Injuries More Likely on Certain Artificial Turf
8. Plavix Can Help Cut Death Risk in Certain Heart Patients
9. The Worst Is Over, but the Road to Growth Is Uncertain - The 17th Annual CFO Rising Conference & Exhibition
10. Perhaps a longer lifespan, certainly a longer health span
11. One in Five Parents Would Spank in Certain Settings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Diabetes Drugs Better for Heart Health, Study Finds
(Date:2/11/2016)... Whippany, New Jersey (PRWEB) , ... February 11, 2016 , ... ... invited to a free CEU seminar titled, “Stroke Management: Time to Act, Time to ... Senior Housing Community in Whippany, N.J. The presenter is Vishal Chedda, president of ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 budget request ... shift more of the cost burden to military beneficiaries. , MOAA’s president, retired ... defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new ... plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the ... recommendations for rhinoplasty surgeons when addressing this vital area. , The upper lateral ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, ... and audits, privacy and security law, and best practices in data breaches for ...
(Date:2/11/2016)... ... 11, 2016 , ... Talix today announced that Clive Fields, ... presenting at the 2016 HIMSS Annual Conference & Exhibition, taking place February 29 ... “ Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. Fields ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the engagement of ... Company,s Global Medical Consultant. Dr. Birgerson will provide ... Company,s clinical operations team to help ensure timely ...
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
(Date:2/11/2016)... Inc. (NASDAQ: IONS ) announced today that it will ... a.m. Eastern Time to discuss its 2015 financial results and ... . A webcast replay will be available for a limited ... A webcast replay will be available for a limited time ... listen to the call by dialing 877-443-5662 or access the ...
Breaking Medicine Technology: